Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress – June 2022

Abstract

In the structure of the incidence of skin tumors, melanoma accounts for a relatively smaller percentage, but that disease is associated with higher risk of an adverse outcome compared with many other malignancies. The study of innovative clinical developments in drug therapy for resectable melanoma, presented at the ASCO Annual Meeting - June 2022, is . The best clinical developments in drug treatment of patients with resectable melanoma were selected for analysis: 1) phase 3 study KEYNOTE-716; 2) PRADO; 3) Neo Trio; 4) SWOG 1512. The presented developments bring extremely promising results for melanoma therapy workflows. The use of cutting edge anti-cancer therapeutics acting on various molecular targets drastically improves the tumor response as well as straitens the total severity of treatment-related adverse events.